The global attenuated vaccines market is expected to expand from US$ 4.45 billion in 2022 to US$ 9.31 billion by 2032 at a compound annual growth rate (CAGR) of 6.8%.Attenuated vaccination helps in preventing ailments like yellow fever, tuberculosis, measles, retroviral, and likewise. Moreover, it has been reported.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global H1N1 vaccines market reached a value of US$ 1.8 Billion in 2020. Looking forward, the global H1N1 vaccines market to exhibit moderate growth during the next five years.
The H1N1 virus is an infectious disease characterized by a persistent cough, high fever, red-watery eyes, body aches and headache. The illness is known to have a detrimental effect on the existing chronic ailments, such as Pneumonia, Chronic Obstructive Pulmonary Disease (COPD) and Bronchitis, and can be fatal in severe cases. H1N1 vaccines are a preventive measure administered through intradermal and intranasal procedures to provide active immunization against the virus.